Successful Treatment of Crizotinib-Induced Fulminant Liver Failure: A Case Report and Review of Literature-Reference-Cited by-同舟云学术

Successful Treatment of Crizotinib-Induced Fulminant Liver Failure: A Case Report and Review of Literature

Published:2020-03-10 Issue: Volume:2020 Page:1-5
ISSN:2090-6587
Container-title:Case Reports in Hepatology
language:en
Short-container-title:Case Reports in Hepatology

Author:

Kreitman Kyle¹,Nair Satheesh P.¹^ORCID,Kothadia Jiten P.¹^ORCID

Affiliation:

1. MUH James D. Eason Transplant Institute, University of Tennessee Health Sciences Center, 1265 Union Avenue, 4 Shorb Tower, Memphis, TN 38104, USA

Abstract

Crizotinib is a first-line tyrosine kinase inhibitor used for the treatment of metastatic lung cancer. Crizotinib-induced hepatotoxicity is a rare event. We report a case of a 46-year-old female with a history of metastatic lung cancer who presented with acute liver failure after being on crizotinib for two months. The medication was discontinued, and she was treated with N-acetylcysteine for seven days. Her liver function tests returned to normal limits after 26 days after admission. The precise mechanism and risk factors of crizotinib-induced hepatotoxicity remain unknown. Physicians should be aware of the potentially lethal side effect caused by crizotinib.

Publisher

Hindawi Limited

Subject

General Medicine

Link

http://downloads.hindawi.com/journals/crihep/2020/8247960.pdf

Reference23 articles.

1. Cancer statistics, 2019

2. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors

3. Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer

4. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A brief overview of drug-induced liver damage;The Egyptian Journal of Internal Medicine;2024-05-30

2. Crizotinib;Reactions Weekly;2023-04-01

3. Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature;BMC Gastroenterology;2022-02-05

4. An Insight on the Pathways Involved in Crizotinib and Sunitinib Induced Hepatotoxicity in HepG2 Cells and Animal Model;Frontiers in Oncology;2022-01-28

5. Cancer stem cell-mediated therapeutic resistance in hepatocellular carcinoma;Hepatoma Research;2022